AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02625480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel (KTE-X19)
Study NCT02625480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT03233399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham TMS3 stimulation
Description: half of the subjects will receive sham stimulation first
Study NCT03233399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
Description: Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
Study NCT00892762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 50 micrograms/ml eye drop solution
Description: BAK-preserved medication
Study NCT02625480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT03233399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS of left or right AG or FC
Description: Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
Study NCT00223145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gy
Description: Radiotherapy to the prostate
Study NCT04231357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma prepared from peripheral blood using single spin centrifugation
Study NCT04231357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: platelet rich plasma prepared from peripheral blood using single spin centrifugation
Study NCT00748397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixture MicroThread (Micro-Macro)
Description: Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
Study NCT01663818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack-It Endovascular Stapler
Study NCT02521753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Intervention also includes weight reduction diet and exercise therapy
Study NCT02521753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Intervention also includes weight reduction diet and exercise therapy
Study NCT02521753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA
Description: Intervention also includes weight reduction diet and exercise therapy
Study NCT01032954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs.
Study NCT04913168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front Line Worker Pilot Project
Description: 13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
Study NCT00223145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 76 Gy
Description: Radiotherapy to the prostate
Study NCT00223145 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 76 Gy
Description: Radiotherapy to the prostate
Study NCT00223145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen blockade
Description: Duration : 6 months
Study NCT01184079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus vaccine
Description: 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
Study NCT01184079 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: quadrivalent human papillomavirus vaccine
Description: 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
Study NCT01028287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
Study NCT04603157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid Exercise Training
Description: Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
Study NCT02613182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001
Study NCT01505582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
Study NCT01505582 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
Study NCT03349086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Exercise
Description: Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
Study NCT03495349 — intervention group
Intervention type: OTHER
Intervention: safety and effectiveness of the usual treatments of diabetic foot infections
Description: clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
Study NCT03340207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumaglide
Description: The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
Study NCT04697082 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open surgery
Description: Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
Study NCT04697082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
Study NCT04697082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal invasive surgery
Description: In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
Study NCT04697082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma administration
Description: Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
Study NCT03595124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO
Study NCT03595124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03596385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: long-term maintenance beta-blocker therapy
Study NCT03013101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study NCT00791453 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education
Description: Patients will receive literacy appropriate health information.
Study NCT03647150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: At enrollment the child will receive a 1 week course of amoxicillin
Study NCT03647150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF)
Description: 1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
Study NCT03647150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Care group
Description: Nutrition education via mother care groups lead by a respected elder in the local community
Study NCT03647150 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mother Care group
Description: Nutrition education via mother care groups lead by a respected elder in the local community
Study NCT03643315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Meal (EX)
Description: 30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
Study NCT03643315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No-Exercise and Meal (NEX)
Description: 30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
Study NCT00294645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transtelephonic monitoring (TTM)
Description: TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
Study NCT00294645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CareLink® Network
Description: Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
Study NCT02693054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HALO
Description: Laser Treatment
Study NCT01543399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: Experimental group will use 2.5mg of tibolone for 30 days
Study NCT01543399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients of the placebo group will use placebo one a day for 30 days
Study NCT01783314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI of liver
Description: MRI of liver with intravenous gadoxetate disodium
Study NCT01783314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI of liver
Description: MRI of liver with intravenous gadoxetate disodium
Study NCT00075114 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bladder Health Class
Description: A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
Study NCT01330628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters
Description: application of laser energy to remove blockage followed by standard balloon angioplasty
Study NCT01330628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty
Description: standard balloon catheters for PTA
Study NCT04854525 — intervention group
Intervention type: RADIATION
Intervention: Pre reconstruction Radiotherapy
Description: Previous PMRT
Study NCT01476319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
Study NCT03112512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optimal PEEP guided by EIT
Description: Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
Study NCT03112512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optimal PEEP guided by G5 ventilator
Description: Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
Study NCT02627547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal training
Description: 5-10 hours of endurance training each week
Study NCT02627547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-training
Description: No training
Study NCT02017392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Lidocaine Cream
Description: Compound Lidocaine Cream ,1-2 grams per person.
Study NCT02047591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing-touch method
Study NCT01192269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Description: 1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
Study NCT01670786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurodesis
Description: Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
Study NCT02511834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST External Support
Study NCT02511834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Surgery
Study NCT02511834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Surgery
Study NCT01097642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
Study NCT01097642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
Study NCT01097642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
Study NCT02761187 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT01796119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Splitting
Description: To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length.
Study NCT01796119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants placed using drilling technique
Description: To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length.
Study NCT03241823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound .
Description: Abdominal ultrasound for each patient before and after treatment.
Study NCT03241823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Model for End-Stage Liver Disease
Description: Model for End-Stage Liver Disease before and after treatment.
Study NCT03241823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibro Scan.
Description: Liver stiffness by Fibro scan before and after treatment.
Study NCT03241823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Child-Turcotte-Pugh score.
Description: Child-Turcotte-Pugh score before and after treatment
Study NCT01984645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
Study NCT02153424 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT00874458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Study NCT00874458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiomammography
Study NCT00874458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Study NCT03540537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient-controlled intravenous analgesia
Description: PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
Study NCT03540537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia
Description: PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
Study NCT03540537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.